CLINICAL NEWS
In this study, the maximum tolerated dose of carfilzomib in combination with thalidomide and dexamethasone was not reached. A fourth
dosing cohort at carfilzomib 56 mg/m2 (n=20) is ongoing.
Overall, the KTd regimen was “active, safe, and well tolerated” as )